Characteristic | Micafungin | Liposomal amphotericin B | Total | |||
---|---|---|---|---|---|---|
 | Non-ICU (n = 127) | ICU (n = 120) | Non-ICU (n = 136) | ICU (n = 110) | Non-ICU (n = 263) | ICU (n = 230) |
Age (years) | Â | Â | Â | Â | Â | Â |
Mean ± standard deviation | 53.1 ± 16.90 | 52.4 ± 19.40 | 53.7 ± 18.74 | 53.4 ± 17.76 | 53.4 ± 17.85 | 52.9 ± 18.60 |
   Median | 54.0 | 54.5 | 55.5 | 56.0 | 55.0 | 56.0 |
   Range | 18.0 to 87.0 | 18.0 to 89.0 | 16.0 to 89.0 | 17.0 to 97.0 | 16.0 to 89.0 | 17.0 to 97.0 |
Male, n (%) | 79 (62.2) | 76 (63.3) | 79 (58.1) | 68 (61.8) | 158 (60.1) | 144 (62.6) |
Female, n (%) | 48 (37.8) | 44 (36.7) | 57 (41.9) | 42 (38.2) | 105 (39.9) | 86 (37.4) |
Race, n (%) | Â | Â | Â | Â | Â | Â |
   Black | 11 (8.7) | 2 (1.7) | 7 (5.1) | 3 (2.7) | 18 (6.8) | 5 (2.2) |
   Caucasian | 84 (66.1) | 65 (54.2) | 97 (71.3) | 56 (50.9) | 181 (68.8) | 121 (52.6) |
   Other | 32 (25.20) | 53 (44.17) | 32 (23.5) | 51 (46.4) | 64 (24.3) | 104 (45.2) |
Region, n (%) | Â | Â | Â | Â | Â | Â |
   Brazil | 37 (29.1) | 18 (15.0) | 42 (30.9) | 15 (13.6) | 79 (30.0) | 33 (14.3) |
   Europe | 37 (29.1) | 46 (38.3) | 43 (31.6) | 34 (30.9) | 80 (30.4) | 80 (34.8) |
   India | 12 (9.4) | 44 (36.7) | 20 (14.7) | 39 (35.5) | 32 (12.2) | 83 (36.1) |
   North America | 11 (8.7) | 6 (5.0) | 12 (8.8) | 7 (6.4) | 23 (8.7) | 13 (5.7) |
   Other | 30 (23.6) | 6 (5.0) | 19 (14.0) | 15 (13.6) | 49 (18.6) | 21 (9.1) |
APACHE II score | Â | Â | Â | Â | Â | Â |
   Mean ± standard deviation | 13.4 ± 6.32 | 18.4 ± 9.39 | 14.1 ± 6.60 | 17.8 ± 9.35 | 13.8 ± 6.46 | 18.1 ± 9.35 |
   Median | 13.0 | 19.0 | 14.0 | 17.0 | 14.0 | 17.5 |
   Range | 0 to 30.0 | 0 to 44.0 | 0 to 37.0 | 0 to 47.0 | 0 to 37.0 | 0 to 47.0 |
Relevant risk factors | Â | Â | Â | Â | Â | Â |
   Catheter present | 95 (75.4) | 116 (96.7) | 93 (68.4) | 105 (95.5) | 188 (71.8) | 221 (96.1) |
   Bone marrow transplant | 4 (3.1) | 2 (1.7) | 2 (1.5) | 1 (0.9) | 6 (2.3) | 3 (1.3) |
   Neutropenia | 26 (20.5) | 6 (5.0) | 21 (15.4) | 4 (3.6) | 47 (17.9) | 10 (4.3) |
   Persistent neutropenia during therapy | 11 (8.8) | 3 (2.5) | 7 (5.3) | 2 (1.9) | 18 (7.0) | 5 (2.2) |
   Acute leukemia | 20 (15.7) | 1 (0.8) | 13 (9.6) | 3 (2.7) | 33 (12.5) | 4 (1.7) |
   Hematological disorder | 37 (29.1) | 7 (5.8) | 24 (17.6) | 8 (7.3) | 61 (23.2) | 15 (6.5) |
   Liver disorder/failure | 1 (0.8) | 0 (0.0) | 2 (1.5) | 0 (0.0) | 3 (1.1) | 0 (0.0) |
   Pancreatitis | 5 (3.9) | 4 (3.3) | 3 (2.2) | 6 (5.5) | 8 (3.0) | 10 (4.3) |
   Renal disorder/failure | 0 (0.0) | 2 (1.7) | 1 (0.7) | 0 (0.0) | 1 (0.4) | 2 (0.9) |
   Solid organ tumor | 23 (18.1) | 12 (10.0) | 27 (19.9) | 23 (20.9) | 50 (19.0) | 35 (15.2) |
   Solid organ transplant | 4 (3.1) | 9 (7.5) | 5 (3.7) | 4 (3.6) | 9 (3.4) | 13 (5.7) |
Antibiotic use | 23 (18.1) | 29 (24.2) | 28 (20.6) | 35 (31.8) | 51 (19.4) | 64 (27.8) |
   Corticosteroid therapy | 14 (11.0) | 22 (18.3) | 20 (14.7) | 17 (15.5) | 34 (12.9) | 39 (17.0) |
   Other immunosuppression | 9 (7.1) | 11 (9.2) | 8 (5.9) | 7 (6.4) | 17 (6.5) | 18 (7.8) |
   Intravenous line/device | 40 (31.5) | 26 (21.7) | 35 (25.7) | 20 (18.2) | 75 (28.5) | 46 (20.0) |
Length of hospital stay | Â | Â | Â | Â | Â | Â |
   Mean ± standard deviation | 21.6 ± 17.77 | 20.0 ± 20.36 | 23.2 ± 20.35 | 27.6 ± 47.59 | 22.5 ± 19.13 | 23.6 ± 36.16 |
   Median | 18.0 | 14.0 | 19.5 | 15.0 | 19.0 | 14.5 |
   Range | 2 to 82.0 | 1 to 126.0 | 1 to 97.0 | 1 to 388.0 | 1 to 97.0 | 1 to 388.0 |